Скачать с ютуб Symposium | BCMA-directed ADCs for the treatment of MM в хорошем качестве

Symposium | BCMA-directed ADCs for the treatment of MM

This independent educational activity was supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity. At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence B-cell maturation antigen (BCMA)-directed therapies in early relapsed/refractory multiple myeloma (RRMM). During the symposium, Martin Kaiser, The Royal Marsden Hospital, London, UK, delivered a presentation on BCMA-directed antibody–drug conjugates (ADCs) for the treatment of MM. In this presentation, Dr Kaiser focused on the potential and evolving role of ADCs in the treatment of multiple myeloma, particularly in comparison to other BCMA-targeting therapies, such as bispecific antibodies and CAR T-cell therapies. The discussion includes the mechanisms of action, recent clinical trial data, toxicity profiles, resistance mechanisms, and future directions for optimizing ADC use. A key topic was belantamab mafodotin, including its efficacy in triplet regimens and its potential role in therapy sequencing.